10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Prevalence of statin intolerance: a meta-analysis

I Bytyci, PE Penson, DP Mikhailidis… - European heart …, 2022 - academic.oup.com
Aims Statin intolerance (SI) represents a significant public health problem for which precise
estimates of prevalence are needed. Statin intolerance remains an important clinical …

Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction

SJ Nicholls, Y Kataoka, SE Nissen, F Prati… - Cardiovascular …, 2022 - jacc.org
Background The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab
produced coronary atheroma regression in statin-treated patients. Objectives The purpose of …

[HTML][HTML] Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

C Reith, C Baigent, L Blackwell, J Emberson, E Spata… - The Lancet, 2022 - thelancet.com
Background Statin therapy is effective for the prevention of atherosclerotic cardiovascular
disease and is widely prescribed, but there are persisting concerns that statin therapy might …

Diagnosis and treatment of acute coronary syndromes: a review

DL Bhatt, RD Lopes, RA Harrington - Jama, 2022 - jamanetwork.com
Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target

J Behbodikhah, S Ahmed, A Elyasi, LJ Kasselman… - Metabolites, 2021 - mdpi.com
Apolipoprotein (apo) B, the critical structural protein of the atherogenic lipoproteins, has two
major isoforms: apoB48 and apoB100. ApoB48 is found in chylomicrons and chylomicron …

[HTML][HTML] Alirocumab and cardiovascular outcomes after acute coronary syndrome

GG Schwartz, PG Steg, M Szarek… - … England Journal of …, 2018 - Mass Medical Soc
Background Patients who have had an acute coronary syndrome are at high risk for
recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a …

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the …

SM Grundy, NJ Stone, AL Bailey, C Beam… - Journal of the American …, 2019 - jacc.org
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on
the Management of Blood Cholesterol: Executive Summary: A Report of the American …

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of …

SM Grundy, NJ Stone, AL Bailey, C Beam… - Journal of the American …, 2019 - jacc.org
The recommendations listed in the present guideline are, whenever possible, evidence
based. An initial extensive evidence review, which included literature derived from research …

Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving …

H Watanabe, T Domei, T Morimoto, M Natsuaki… - Jama, 2019 - jamanetwork.com
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …